Cullinan Therapeutics Shares Fell After Data Delay
The company pushed back its rheumatoid arthritis data release to December, citing a need for further evaluation.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you believe recent stock price drops present a good opportunity to buy shares?
Cullinan Therapeutics saw its stock price decline by a combined 34% over Wednesday and Thursday following a delay in clinical data reporting for its rheumatoid arthritis candidate, CLN-978. The company rescheduled the update from the third quarter to December.
Why it matters
The shift in the data release timeline, coupled with investor concern over grade 3 or higher adverse events observed in the company's separate zipalertinib lung cancer trials, has placed downward pressure on the firm's equity. This performance comes after a year of strong growth, with shares having gained 55% year-to-date prior to the recent sell-off.
Cullinan Therapeutics reported a stock decline of 5% at the time of writing following two days of significant losses. Investors are awaiting multi-dose and single-target-dose results for CLN-978, now slated for December.
The players
Cullinan Therapeutics
A biopharmaceutical company developing a pipeline of targeted oncology and autoimmune therapies.
The details
CLN-978 is a therapeutic candidate currently being investigated for the treatment of rheumatoid arthritis, an autoimmune condition where the immune system attacks joints. The company's recent safety results for its lung cancer program, zipalertinib, reported high rates of grade 3 or higher adverse events—a classification for severe or medically significant events that are not immediately life-threatening but require intervention. The decision to delay the CLN-978 data release aims to allow more time for review.
Timeline
Wednesday, September 23, 2026: CGEM stock fell 22 percent.
Thursday, September 24, 2026: CGEM stock fell 12 percent.
November 8, 2026: The company plans to present velinotamig data at a medical meeting.
December 2026: The company intends to report results for CLN-978 and provide updated follow-up data for CLN-049.
The Tech Race
The firm operates within a highly competitive landscape for autoimmune and oncology therapies where clinical safety readouts dictate market valuation. This recent volatility underscores the sensitivity of investor confidence to shifts in research reporting timelines for mid-stage drug candidates.
The company's pipeline adjustments primarily affect investors and stakeholders monitoring the development progress of CLN-978 and zipalertinib. There is currently no impact on patient access or treatment availability, as these therapies remain in the research and clinical trial stages.
The takeaway
The firm's upcoming December release will clarify the trajectory of CLN-978 and serve as a benchmark for its recovery. Investors should watch the November 8 presentation of velinotamig as an indicator of the company's broader operational stability.
What happens next
Cullinan Therapeutics is scheduled to present data for velinotamig on November 8, 2026, followed by the reports for CLN-978 and CLN-049 in December 2026.
Further reading
For broader trends in clinical research timelines, explore the Biotech section.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Do you believe recent stock price drops present a good opportunity to buy shares?
